Wednesday, October 16, 2019 Daily Archives

Using Slope Spectroscopy for Faster, Repeatable, More Accurate Protein Concentration Measurements

This webcast features: Joe Ferraiolo, Bioanalytics Applications Manager, Repligen Traditional capture chromatography titer measurements that involve dilution requirements represent the highest single source of error in traditional UV analysis. Slope spectroscopy requires no sample preparation or dilution, saving substantial time without changing any other aspects of the assay. This webinar will demonstrate how variable pathlength slope spectroscopy using the SoloVPE™ device can significantly reduce sample prep and process time, while maintaining high repeatability and accuracy. Watch the recorded webcast below.

J&J downgrades biosimilar threat as Q3 pulls in $10bn+ in pharma sales

J&J reported its sixth consecutive quarter with sales above $10 billion in its pharmaceutical division and has lowered its biosimilar headwind forecast to $2 billion. For the third quarter 2019, Johnson & Johnson (J&J) reported sales across all its units of $20.7 billion (€18.8 billion). Its pharmaceutical division pulled in roughly half of the total, $10.8 billion, up 5.1% on the same quarter last year. “This was our sixth consecutive quarter with sales above $10 billion,” Jennifer Taubert, EVP and…

Big M&A: Alexion in $930m Achillion buy, UCB bids $2.1bn for Ra

In a big week for Big Pharma M&A, Alexion has agreed to buy Factor D inhibitor developer Achillion and UCB will add a late-stage FcRn targeting antibody through its acquisition of Ra Pharmaceuticals. Alexion Pharmaceuticals, which itself has been in the news recently as a potential target for M&A-hungry Amgen, announced today it has agreed to buy clinical-stage biopharmaceutical company Achillion Pharmaceuticals for approximately $930 million (€842 million). The deal adds oral small molecule Factor D inhibitors to treat people…